RNAM
Avidity Biosciences, Inc.
No data for this timeframe.
Vol
Inst. Holders8 funds
Inst. Value$1.5B
Inst. Activity3 buys / 3 sells
SEC Reports2
Recent Activity
Mar 9, 2026
SEC
Avidity Biosciences, Inc. (RNAM) has filed Form 15-12G to terminate the registration of its common stock under Section 1
15-12G — Impact 8/10
Feb 28, 2026
SEC
Three major institutions, including sovereign wealth fund Norges Bank and quant giant RenTech, initiated new positions i
INST-CLUSTER — Impact 7/10
Feb 27, 2026
Insider
Kaye Edward M. MD sold 6,692 shares
Director @ $0.00 ($0.00)
Feb 27, 2026
Insider
Calderaro Charles III sold 98,547 shares
Chief Technical Officer @ $0.00 ($0.00)
Feb 27, 2026
Insider
MacLean Michael F sold 133,977 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
NORGES BANK — NEW
3,046,388 shares ($219.7M)
Inst.
MORGAN STANLEY — ADD
1,092,482 shares ($78.8M)
May 6, 2026
earnings_calendar
RNAM Q1 2026 Earnings Scheduled — 2026-05-06
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$72.71 (Nov 2025)
Current $72.82
Low $72.00
Median $72.00
High $75.00
7 analysts
$72.00
$75.00
Analyst Ratings
2Strong Buy
6Buy
12Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 11, 2025 | Chardan Capital | MAINTAIN | Neutral → Neutral |
| Oct 29, 2025 | TD Cowen | DOWNGRADE | Buy → Hold |
| Oct 28, 2025 | Chardan Capital | DOWNGRADE | Buy → Neutral |
| Oct 28, 2025 | RBC Capital | DOWNGRADE | Outperform → Sector Perform |
| Oct 27, 2025 | Citigroup | DOWNGRADE | Buy → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next FY | $-3.80 | $-4.84 — $-2.60 | 25% YoY | 6 |
| Next Q | $-1.33 ▼ -1.1% | $-1.61 — $-1.01 | -10% YoY | 6 |
| Current FY | $-5.05 ▼ -2.7% | $-6.53 — $-3.24 | -2% YoY | 8 |
| Current Q | $-1.30 ▼ -1.6% | $-1.59 — $-0.98 | -45% YoY | 6 |
Latest Reports
BEARISH
15-12G
8/10
Avidity Biosciences, Inc. (RNAM) has filed Form 15-12G to terminate the registration of its common stock under Section 1
Mar 9, 2026
MIXED
INST-CLUSTER
7/10
Three major institutions, including sovereign wealth fund Norges Bank and quant giant RenTech, initiated new positions i
Feb 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $984.5M | ADD |
| NORGES BANK | $219.7M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $85.2M | NEW |
| MORGAN STANLEY | $78.8M | ADD |
| BANK OF AMERICA CORP | $51.0M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 27, 2026 | Kaye Edward | D | $0.00 |
| Feb 27, 2026 | Calderaro Charles | D | $0.00 |
| Feb 27, 2026 | MacLean Michael | D | $0.00 |
| Feb 27, 2026 | Hughes Steven | D | $0.00 |
| Feb 27, 2026 | WILSON TROY | D | $0.00 |
8 institutional holders with $1.5B total value (20,115,379 shares) as of 2025-Q4. Top holders: VANGUARD, NORGES, CHARLES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 13,649,250 | $984.5M | 67.9% | ADD +42.9% |
| 2 | NORGES BANK | 3,046,388 | $219.7M | 15.1% | NEW |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,181,661 | $85.2M | 5.9% | NEW |
| 4 | MORGAN STANLEY | 1,092,482 | $78.8M | 5.4% | ADD +58.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 706,665 | $51.0M | 3.5% | TRIM -59.0% |
| 6 | WELLS FARGO & COMPANY/MN | 210,604 | $15.2M | 1.0% | TRIM -31.5% |
| 7 | FMR LLC | 183,229 | $13.2M | 0.9% | NEAR_EXIT -99.2% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 45,100 | $3.3M | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 3,046,388 | — | $219.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 691,512 | 1,092,482 | +58.0% | $78.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,725,186 | 706,665 | -59.0% | $51.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 307,394 | 210,604 | -31.5% | $15.2M | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 21,585,984 | 183,229 | -99.2% | $13.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 45,100 | — | $3.3M | 2025-Q4 |
| FMR LLC | ADD | 16,185,791 | 21,585,984 | +33.4% | $940.5M | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 9,248,302 | 13,219,759 | +42.9% | $576.0M | 2025-Q3 |
| UBS Group AG | DOUBLED | 596,554 | 1,315,859 | +120.6% | $57.3M | 2025-Q3 |
| MORGAN STANLEY | ADD | 445,880 | 691,512 | +55.1% | $30.1M | 2025-Q3 |
| NORGES BANK | EXIT | 995,118 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 995,118 | — | $28.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 28,000 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 205,906 | 597,995 | +190.4% | $17.7M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,213,776 | 525,696 | -56.7% | $15.5M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 172,570 | 220,786 | +27.9% | $6.5M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 502,175 | 86,882 | -82.7% | $2.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 132,560 | 28,000 | -78.9% | $826.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 211,200 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 724,787 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 611,237 | 1,213,776 | +98.6% | $35.3M | 2024-Q4 |
| NORGES BANK | TRIM | 1,046,856 | 724,787 | -30.8% | $21.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 61,000 | 502,175 | +723.2% | $14.6M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 141,900 | 211,200 | +48.8% | $6.1M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 990,182 | — | $45.5M | 2024-Q3 |
17 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Kaye Edward M. MD | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Calderaro Charles III | Chief Technical Officer | D | 98,547 | $0.00 | $0.00 |
| Feb 27, 2026 | MacLean Michael F | Chief Financial Officer | D | 133,977 | $0.00 | $0.00 |
| Feb 27, 2026 | Hughes Steven George | Chief Medical Officer | D | 115,857 | $0.00 | $0.00 |
| Feb 27, 2026 | WILSON TROY EDWARD | Director | D | 65,091 | $0.00 | $0.00 |
| Feb 27, 2026 | Kim Jean Jinsun | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Thompson Tamar | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Thompson Tamar | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | MacLean Michael F | Chief Financial Officer | D | 92,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Skerjanec Simona | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Skerjanec Simona | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | Hughes Steven George | Chief Medical Officer | D | 73,342 | $0.00 | $0.00 |
| Feb 27, 2026 | Moriarty John B | Chief Legal Officer | D | 92,054 | $0.00 | $0.00 |
| Feb 27, 2026 | Moriarty John B | Chief Legal Officer | D | 50,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Flanagan W. Michael | Chief Scientific Officer | D | 150,365 | $0.00 | $0.00 |
| Feb 27, 2026 | Flanagan W. Michael | Chief Scientific Officer | D | 25,000 | $0.00 | $0.00 |
| Feb 27, 2026 | WILSON TROY EDWARD | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | Gallagher Kathleen P. | Chief Program Officer | D | 80,303 | $0.00 | $0.00 |
| Feb 27, 2026 | Henig Noreen | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Kim Jean Jinsun | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | LEVIN ARTHUR A | Director | D | 16,562 | $0.00 | $0.00 |
| Feb 27, 2026 | Kaye Edward M. MD | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | BOESS CARSTEN | Director | D | 6,692 | $0.00 | $0.00 |
| Feb 27, 2026 | Mosbrooker Eric | Chief Commercial Officer | D | 79,413 | $0.00 | $0.00 |
| Feb 27, 2026 | Calderaro Charles III | Chief Technical Officer | D | 80,000 | $0.00 | $0.00 |
| Feb 27, 2026 | McCarthy Teresa | Chief Human Resources Officer | D | 165,296 | $0.00 | $0.00 |
| Feb 27, 2026 | McCarthy Teresa | Chief Human Resources Officer | D | 106,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Boyce Sarah | President and CEO | D | 474,861 | $0.00 | $0.00 |
| Feb 27, 2026 | Boyce Sarah | President and CEO | D | 386,015 | $0.00 | $0.00 |
| Feb 27, 2026 | Gallagher Kathleen P. | Chief Program Officer | D | 22,321 | $0.00 | $0.00 |
| Feb 27, 2026 | Henig Noreen | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | LEVIN ARTHUR A | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | BOESS CARSTEN | Director | D | 10,034 | $0.00 | $0.00 |
| Feb 27, 2026 | Mosbrooker Eric | Chief Commercial Officer | D | 177,188 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 0 neutral. Avg impact: 7.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2025): 40% buy across 20 analysts — 2 strong buy, 6 buy, 12 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$72.71 mean target (Nov 2025)
$72.00 Low
$75.00 High
| Metric | Value |
|---|---|
| Current Price | $72.82 |
| Target Low | $72.00 |
| Target Mean | $72.71 |
| Target Median | $72.00 |
| Target High | $75.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next FY 2027-12-31 |
$-3.80 | $-4.84 | $-2.60 | 24.9% | -0.0% | 1↑ 0↓ | $0.3B | 1979.9% | 6 |
| Next Q 2026-06-30 |
$-1.33 | $-1.61 | $-1.01 | -10.2% | -1.1% | 1↑ 0↓ | $0.0B | -40.9% | 6 |
| Current FY 2026-12-31 |
$-5.05 | $-6.53 | $-3.24 | -1.7% | -2.7% | 1↑ 1↓ | $0.0B | -24.1% | 8 |
| Current Q 2026-03-31 |
$-1.30 | $-1.59 | $-0.98 | -45.0% | -1.6% | 1↑ 0↓ | $0.0B | 44.6% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.305 | |
| 7d ago | $-1.285 | -0.020 |
| 30d ago | $-1.285 | -0.020 |
| 60d ago | $-1.285 | -0.020 |
| 90d ago | $-1.285 | -0.020 |
12 analyst firms have rated this stock: 0 upgrades, 9 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 11, 2025 | Chardan Capital | MAINTAIN | Neutral | Neutral |
| Oct 29, 2025 | TD Cowen | DOWNGRADE | Buy | Hold |
| Oct 28, 2025 | Chardan Capital | DOWNGRADE | Buy | Neutral |
| Oct 28, 2025 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Oct 27, 2025 | Citigroup | DOWNGRADE | Buy | Neutral |
| Oct 27, 2025 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Oct 27, 2025 | Raymond James | DOWNGRADE | Strong Buy | Market Perform |
| Oct 27, 2025 | Bernstein | DOWNGRADE | Outperform | Market Perform |
| Oct 27, 2025 | Needham | DOWNGRADE | Buy | Hold |
| Oct 27, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 22, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Sep 17, 2025 | Roth Capital | INITIATE | — | Buy |
| Sep 15, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Sep 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 10, 2025 | Needham | MAINTAIN | Buy | Buy |
| Sep 10, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2026 | 2 | 6 | 12 | 0 | 0 | 40% | |
| Jan 1, 2026 | 2 | 6 | 12 | 0 | 0 | 40% | |
| Dec 1, 2025 | 2 | 6 | 12 | 0 | 0 | 40% | |
| Nov 1, 2025 | 4 | 8 | 9 | 0 | 0 | 57% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
RNAM Q1 2026 Earnings Scheduled — 2026-05-06